Company Description
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases.
Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa.
The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication.
In addition, it develops preclinical RASP platform, including ADX 248, ADX 743, ADX 631, ADX 246, and other product candidates in development for inflammatory and metabolic diseases.
The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014.
Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
| Country | United States |
| Founded | 2004 |
| IPO Date | May 2, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Todd Brady |
Contact Details
Address: 131 Hartwell Avenue, Suite 320 Lexington, Massachusetts 02421 United States | |
| Phone | 781 761 4904 |
| Website | aldeyra.com |
Stock Details
| Ticker Symbol | ALDX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001341235 |
| CUSIP Number | 01438T106 |
| ISIN Number | US01438T1060 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Todd C. Brady M.D., Ph.D. | Chief Executive Officer, President and Director |
| David Burke | Head of Investor Relations |
| Laura Nichols | Operations Manager |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 6, 2025 | 8-K | Current Report |
| Apr 25, 2025 | ARS | Filing |
| Apr 25, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 25, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 17, 2025 | 8-K | Current Report |
| Apr 7, 2025 | SCHEDULE 13G/A | Filing |
| Apr 3, 2025 | 8-K | Current Report |
| Mar 28, 2025 | 10-K/A | [Amend] Annual report |
| Feb 28, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 28, 2025 | 10-K | Annual Report |